Vitamin K2: Benefits, MK-7, Foods, Dosage and Safety
Vitamin K2 explained: MK-4 and MK-7, bone and artery trials, food sources, dosage, labels and anticoagulant interactions.
- Published
- Last reviewed
- Reading time
- 7 min
- Sources cited
- 7

On this page
Vitamin K2 is the name for a family of vitamin K compounds called menaquinones. MK-4 and MK-7 are two familiar forms. They support the activation of vitamin-K-dependent proteins and have been studied for bone and cardiovascular outcomes.
K2 is worth understanding because the human evidence is developing, especially for coronary calcification. It is also a nutrient whose role, food sources, supplement doses and medication interactions are frequently oversimplified.
K1, K2 and potassium are different things
| Name | What it is | Where it commonly appears |
|---|---|---|
| Vitamin K1 | Phylloquinone | Leafy vegetables and some oils |
| Vitamin K2 | Menaquinone family | Certain fermented and animal foods; supplements |
| MK-4 | One K2 form | Animal foods and nutritional or treatment formulations |
| MK-7 | Another K2 form | Natto and many once-daily supplements |
| Potassium | A mineral with chemical symbol K | Many foods and separate mineral products |
It is inaccurate to treat K2 and potassium as interchangeable. It is also too simple to say K1 works only in blood while K2 works only in bone or arteries. Vitamin K biology spans multiple tissues and proteins.
What does K2 do in the body?
Vitamin K supports an enzyme reaction called gamma-carboxylation. This changes particular proteins so they can perform their functions. Coagulation proteins, osteocalcin and matrix Gla protein are among the relevant targets.
Osteocalcin is associated with bone biology. Matrix Gla protein is involved in limiting inappropriate calcification. These pathways explain why K2 has attracted interest in bone and vascular research.
Activation of a protein is an intermediate biological effect. To establish a health benefit, studies must also ask whether bone structure, calcification progression or clinical events change.
Bone benefits: what has been tested?
In a three-year study of 244 healthy postmenopausal women, 180 micrograms MK-7 daily reduced bone loss at some sites. This is a useful positive finding for that population and regimen.
A different three-year study in women with osteopenia used 375 micrograms/day with background calcium and D. It improved osteocalcin carboxylation but did not clearly preserve density or microarchitecture beyond the background regimen.
A K2 osteoporosis meta-analysis reported favorable lumbar-density findings, while its fracture conclusions depended on study inclusion. This is why a supplement should not be advertised as a proven universal substitute for osteoporosis treatment.
Cardiovascular research: the new randomized findings
| Study | Intervention and population | Main result |
|---|---|---|
| AVADEC | MK-7 plus D in older men with valve calcification | Neutral for the primary aortic-valve outcome |
| VitaK-CAC, 2026 | MK-7 in patients with coronary disease and calcium scores 50–400 | Slower coronary-calcium progression |
| DANCODE, 2026 | MK-7 plus D3 in patients with severe coronary calcium | Slower calcium-score progression over two years |
The VitaK-CAC and DANCODE findings strengthen the case for further clinical research. They do not establish that K2 removes existing plaque or reduces heart attacks. The arterial-calcification guide explains the numbers and why the endpoints differ from AVADEC.
MK-4 versus MK-7
MK-7 persists longer in circulation in comparative research, making it convenient for once-daily products. MK-4 has a different pharmacokinetic and clinical-study history.
Dose units matter. A 45 mg MK-4 treatment regimen contains 45,000 micrograms. It cannot be equated with a 120-microgram MK-7 supplement by comparing capsule counts.
The MK-4/MK-7 comparison covers absorption, persistence, trial doses and quality claims. A longer half-life alone does not prove superior outcomes for every indication.
How much K2 do adults need?
There is no separately established universal K2-only requirement. US adequate intakes are 120 micrograms/day for adult men and 90 for adult women, but those values refer to total vitamin K. They should not be relabeled as required MK-7 supplement doses. Vitamin K reference
Trials use different doses because they ask different questions. A 180-microgram bone regimen, a 360-microgram coronary regimen and a 720-microgram K2/D3 regimen are not steps on a universal consumer dose ladder.
Choose a product amount around the purpose of use and the available evidence. If K2 is combined with D3, there is no established matching ratio that makes every D3 dose appropriate.
Food sources: natto, cheese, eggs and meat
Natto is a concentrated MK-7 source. Animal foods can provide MK-4, and fermented foods may contain other menaquinones depending on production. Cheese values vary substantially with culture, maturation and the forms measured.
Leafy greens remain valuable vitamin K foods even though their main contribution is K1. A varied diet should not be dismissed because a supplement advertisement focuses on K2.
Our food-source guide includes serving amounts and explains why some database values describe MK-4 only rather than a food's total K2 content.

Is low K2 intake the same as clinical vitamin K deficiency?
No. Clinically important vitamin K deficiency and research evidence of less complete carboxylation of extrahepatic proteins are different concepts. A protein-marker change does not automatically create a recognized disease diagnosis or a supplement requirement for every person.
Diet, malabsorption, medicines and clinical circumstances can affect vitamin K status. If a deficiency is suspected, the assessment should address the cause rather than relying on an online checklist of vague symptoms.
Does K2 cause blood clots?
Vitamin K is necessary for normal coagulation. That role is not equivalent to proving that ordinary K2 supplementation causes thrombosis in healthy people. However, interference with vitamin K antagonist treatment is a real and clinically important concern.
An MK-7 anticoagulation study found that small supplemental amounts could alter anticoagulant sensitivity in some participants. This is why people taking warfarin or related medicines should consult their treatment team before adding K2.
Do not stop prescribed treatment or suddenly remove vitamin-K-containing foods. Consistency and a managed plan matter more than attempting to eliminate the nutrient without advice.
What should a good K2 label show?
Look for the exact form, amount per daily serving and dose unit. If a manufacturer makes an all-trans, purity or stability claim, look for relevant supporting specifications and batch information.
The capsule's other ingredients still matter. A D3/K2 product may contain a higher D3 dose than you need, while an iodine-containing formula adds a separate thyroid-related consideration. A magnesium-containing formula should identify the nutrient amount clearly.
For a suitable D3/MK-7/L-threonate combination, DoNotAge is our first option to assess. We have an affiliate relationship with the brand. The buying guide compares the complete formulations rather than ranking K2 by its name alone.

Choosing the next step
Start with the reason for supplementation, review diet and medication, then identify a form and amount that fit. Use the D3/K2 guide for pairing questions, the bone review for skeletal outcomes and the safety guide for interaction concerns.
Research and sources
Explore the D3, K2 and magnesium research data center for study summaries, population and formulation details, limitations and original publication links. Source links throughout this guide point to the relevant evidence or official guidance.
Frequently asked questions
Is vitamin K2 the same as potassium?
Do leafy vegetables contain K2?
Can K2 dissolve bone spurs?
Is 90–120 micrograms a required K2 supplement dose?
Can vitamin K2 cause blood clots?
Should I take both MK-4 and MK-7?
Sources & article history
Sources (7)
-
Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2013;24(9):2499-507.
-
The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2021;32(1):185-191.
-
Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials Frontiers in public health. 2022;10:979649.
-
Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial JAMA cardiology. 2026;11(8):719-726.
-
Vitamin K2 and D3 Supplementation in Patients With Severe Coronary Artery Calcification: The DANCODE Trial Circulation. 2026;:10.1161/CIRCULATIONAHA.126.082363.
-
Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial Circulation. 2022;145(18):1387-1397.
-
Effect of low-dose supplements of menaquinone-7 (vitamin K2 ) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers Journal of thrombosis and haemostasis : JTH. 2013;11(6):1085-92.




